Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | INCLIVA |
| Repositorio: | r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| OAI Identifier: | oai:incliva.fundanetsuite.com:p17525 |
| Acceso en línea: | https://incliva.portalinvestigacion.com/publicaciones/17525 |
| Access Level: | acceso abierto |
| Palabra clave: | Calcitonin gene-related peptide Monoclonal antibodies Migraine 65 years old Real-world |
| id |
ES_641c312bb0085e0733db6b8cec2c31d6 |
|---|---|
| oai_identifier_str |
oai:incliva.fundanetsuite.com:p17525 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patientsMuñoz-Vendrell ACampoy SCaronna EAlpuente ATorres-Ferrus MNieves Castellanos COlivier MCampdelacreu JPrat JCamiña Muñiz JMolina Martínez FJMínguez-Olaondo ARuibal Salgado MSantos Lasaosa SNavarro Pérez MPMorollón NLópez Bravo ACano Sánchez LMGarcía-Sánchez SMGarcía-Ull JRubio-Flores LGonzalez-Martinez AQuintas SEchavarría Íñiguez AGil Luque SCastro-Sánchez MVAdell Ortega VGarcía Alhama JBerrocal-Izquierdo NBelvís RDíaz-Insa SPozo-Rosich PHuerta-Villanueva MCalcitonin gene-related peptideMonoclonal antibodiesMigraine65 years oldReal-worldBackground Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results A total of 162 patients were included, median age 68 years (range 65-87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.17.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days >= 30%,>= 50%,>= 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice.BMC2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/17525JOURNAL OF HEADACHE AND PAINISSN: 11292369ISSNe: 11292377reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p175252026-06-07T16:35:31Z |
| dc.title.none.fl_str_mv |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients |
| title |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients |
| spellingShingle |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients Muñoz-Vendrell A Calcitonin gene-related peptide Monoclonal antibodies Migraine 65 years old Real-world |
| title_short |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients |
| title_full |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients |
| title_fullStr |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients |
| title_full_unstemmed |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients |
| title_sort |
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients |
| dc.creator.none.fl_str_mv |
Muñoz-Vendrell A Campoy S Caronna E Alpuente A Torres-Ferrus M Nieves Castellanos C Olivier M Campdelacreu J Prat J Camiña Muñiz J Molina Martínez FJ Mínguez-Olaondo A Ruibal Salgado M Santos Lasaosa S Navarro Pérez MP Morollón N López Bravo A Cano Sánchez LM García-Sánchez SM García-Ull J Rubio-Flores L Gonzalez-Martinez A Quintas S Echavarría Íñiguez A Gil Luque S Castro-Sánchez MV Adell Ortega V García Alhama J Berrocal-Izquierdo N Belvís R Díaz-Insa S Pozo-Rosich P Huerta-Villanueva M |
| author |
Muñoz-Vendrell A |
| author_facet |
Muñoz-Vendrell A Campoy S Caronna E Alpuente A Torres-Ferrus M Nieves Castellanos C Olivier M Campdelacreu J Prat J Camiña Muñiz J Molina Martínez FJ Mínguez-Olaondo A Ruibal Salgado M Santos Lasaosa S Navarro Pérez MP Morollón N López Bravo A Cano Sánchez LM García-Sánchez SM García-Ull J Rubio-Flores L Gonzalez-Martinez A Quintas S Echavarría Íñiguez A Gil Luque S Castro-Sánchez MV Adell Ortega V García Alhama J Berrocal-Izquierdo N Belvís R Díaz-Insa S Pozo-Rosich P Huerta-Villanueva M |
| author_role |
author |
| author2 |
Campoy S Caronna E Alpuente A Torres-Ferrus M Nieves Castellanos C Olivier M Campdelacreu J Prat J Camiña Muñiz J Molina Martínez FJ Mínguez-Olaondo A Ruibal Salgado M Santos Lasaosa S Navarro Pérez MP Morollón N López Bravo A Cano Sánchez LM García-Sánchez SM García-Ull J Rubio-Flores L Gonzalez-Martinez A Quintas S Echavarría Íñiguez A Gil Luque S Castro-Sánchez MV Adell Ortega V García Alhama J Berrocal-Izquierdo N Belvís R Díaz-Insa S Pozo-Rosich P Huerta-Villanueva M |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Calcitonin gene-related peptide Monoclonal antibodies Migraine 65 years old Real-world |
| topic |
Calcitonin gene-related peptide Monoclonal antibodies Migraine 65 years old Real-world |
| description |
Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results A total of 162 patients were included, median age 68 years (range 65-87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.17.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days >= 30%,>= 50%,>= 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://incliva.portalinvestigacion.com/publicaciones/17525 |
| url |
https://incliva.portalinvestigacion.com/publicaciones/17525 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
BMC |
| publisher.none.fl_str_mv |
BMC |
| dc.source.none.fl_str_mv |
JOURNAL OF HEADACHE AND PAIN ISSN: 11292369 ISSNe: 11292377 reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname:INCLIVA |
| instname_str |
INCLIVA |
| reponame_str |
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| collection |
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869409621888729088 |
| score |
15,81155 |